Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Dose-Escalating, Investigator Initiated Trial to Evaluate the Safety and Efficacy of ZM-02 in Retinitis Pigmentosa

NCT06292650 is registered in ClinicalTrials.gov with Zhongmou Therapeutics as lead sponsor.

NCT NCT06292650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06292650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Dose-Escalating, Investigator Initiated Trial to Evaluate the Safety and Efficacy of ZM-02 in Retinitis Pigmentosa
Lead sponsor
Zhongmou Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
February 25, 2024
Completion date
December 25, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa